By Huang Jianwen King & Wood Mallesons’ Commercial & Regulatory Group
O
n 6 June 2016, 7 months after the China Food and Drug Administration (“CFDA”) published the Pilot Plan for the Drug Marketing Authorization Holder Mechanism (Draft for Public Opinions) (“Draft for Public Opinions”), the General Office of the State